Topiramate, acupuncture, and BoNT‐A for chronic migraine: a network meta‐analysis

2021 ◽  
Author(s):  
Hui Zheng ◽  
Shi‐Le Huang ◽  
Yao‐Yao Chen ◽  
Tai‐Chun Tang ◽  
Di Qin ◽  
...  
Keyword(s):  
Chronic Migraine ◽  
Meta Analysis

scholarly journals Occipital Nerve Stimulation for Chronic Migraine—A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0116786 ◽  
Author(s):  
Yen-Fu Chen ◽  
George Bramley ◽  
Gemma Unwin ◽  
Dalvina Hanu-Cernat ◽  
Janine Dretzke ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Migraine ◽  
Nerve Stimulation ◽  
Meta Analysis ◽  
Occipital Nerve Stimulation ◽  
Occipital Nerve

scholarly journals CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis

2019 ◽  
Vol 9 (2) ◽  
pp. e01215 ◽  
Author(s):  
Lin Han ◽  
Yao Liu ◽  
Hai Xiong ◽  
Peiwei Hong
Keyword(s):  
Monoclonal Antibody ◽  
Chronic Migraine ◽  
Meta Analysis ◽  
Preventive Treatment

scholarly journals Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yao-Yao Chen ◽  
Xiao-Qian Ye ◽  
Tai-Chun Tang ◽  
Tian-Wei She ◽  
Min Chen ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Chronic Migraine ◽  
Botulinum Neurotoxin ◽  
Meta Analysis ◽  
Preventive Treatment ◽  
Calcitonin Gene Related Peptide ◽  
Controlled Trials ◽  
Botulinum Neurotoxin A ◽  
Related Peptide ◽  
Calcitonin Gene

Purpose: Calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are new agents approved by the US Food and Drug Administration for preventive treatment of chronic migraine. Comparison between CGRPmAbs and previously approved Botulinum neurotoxin A (BoNT-A) will inform optimal preventive treatment of chronic migraine, but head-to-head trials are lacking. We therefore aimed to perform adjusted indirect comparison between CGRPmAbs and BoNT-A through a meta-analysis.Methods: OVID MEDLINE, EMBASE and the Cochrane central register of controlled trials, clinical registries, and government websites were searched from inception to September 2019. Randomized controlled trials comparing CGRPmAbs or BoNT-A with placebo in the preventive treatment of chronic migraine were included. The primary outcomes were headache days and migraine days measured at week 12. Data were synthesized by using a frequentist approach; and the treatments were ranked by P-score.Results: We included 10 trials (n = 4,678) after screening 1049 candidates. Six trials were with low risk of bias. Fremanezumab had an effect similar to BoNT-A in the reduction of headache days at week 12 (standard mean difference [SMD] 0.08, 95%CI -0.55 to -0.7). Galcanezumab reduced more migraine days than BoNT-A at week 12 (SMD, -0.94, 95%CI −1.24 to −0.63); fremanezumab showed similar findings (SMD, −0.55, 95%CI −0.85 to −0.24). Galcanezumab and fremanezumab had better effect in mitigating headache impact at week 12. CGRPmAbs and BoNT-A had similar adverse event rate.Conclusion: CGRPmAbs and BoNT-A had similar effect in the preventive treatment of chronic migraine. BoNT-A might be preferentially selected owing to its cost-effectiveness profiles. Further studies with direct comparison of the two treatments are warranted.

scholarly journals High Efficacy of OnabotulinumtoxinA Treatment in Patients With Comorbid Migraine and Depression: A Meta-analysis

2020 ◽  
Author(s):  
Oreste Affatato ◽  
Thiago C. Moulin ◽  
Claudia Pisanu ◽  
Victoria S. Babasieva ◽  
Marco Russo ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Chronic Migraine ◽  
Empirical Bayes ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
Major Depressive ◽  
Bayes Model ◽  
Vas Scores

Abstract Background: Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migraine and depression. While many studies have addressed the effect of onabotulinumtoxinA in migraine or depression separately, a growing body of evidences suggest benecial effects also for patients comorbid with migraine and depression. The current meta-analysis systematically investigates to what extent onabotulinumtoxinA is efficient in migraineurs with depression.Methods: A systematic literature search was performed based on PubMed, Scopus and Web of Science from the earliest date till October 30th, 2020. Mean, standard deviation (SD) and sample size have been used to evaluate improvement in depressive symptoms and migraine using random-effects empirical Bayes model. Results: Our search retrieved 259 studies, eight of which met inclusion criteria. OnabotulinumtoxinA injections administered to patients with both chronic migraine and major depressive disorder led to mean reduction of -8.94 points (CI: [-10.04, -7.84], p < 0:01) in the BDI scale, of -5.90 points (CI: [-9.92, -1.88], p < 0:01) in the BDI-II scale and of -6.19 points (CI: [-9.52, -2.86], p < 0:01) in the PHQ-9 scale, when evaluating depressive symptoms. In the case of the migraine-related symptoms, we found mean reductions of -4.10 (CI: [-7.31, -0.89], p = 0.01) points in the HIT6 scale, -32.05 (CI: [-55.96, -8.14], p = 0.01) in the MIDAS scale, -1.7 (CI: [-3.27, -0.13], p = 0.03) points in the VAS scale and of -6.27 (CI: [-8.48, -4.07], p < 0:01) migraine episodes per month. Comorbid patients showed slightly better improvements in BDI, HIT6 scores and migraine frequency compared to monomorbid patients. The latter group manifested better results in MIDAS and VAS scores. Conclusion: Treatment with onabotulinumtoxinA leads to a signicant reduction of disease severity of both chronic migraine and major depressive disorder in patients comorbid with both diseases. Comparative analyses suggest an equivalent strong effect in monomorbid and comorbid patients, with benecial effects specically seen for certain migraine features.

Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies

Cephalalgia ◽  
2019 ◽  
Vol 40 (5) ◽  
pp. 503-516 ◽  
Author(s):  
Jingjing Xu ◽  
Fanyi Kong ◽  
Dawn C Buse
Keyword(s):  
Risk Factors ◽  
Systematic Review ◽  
Cohort Studies ◽  
Chronic Migraine ◽  
Risk Ratio ◽  
Household Income ◽  
Meta Analysis ◽  
Episodic Migraine ◽  
Annual Household Income ◽  
Increased Risk

Background and purpose An estimated 2.5–3.1% of people with episodic migraine develop chronic migraine in a year. Several risk factors are associated with an increased risk for this transformation. We conducted a systematic review and meta-analysis to provide quantitative and qualitative data on predictors of this transformation. Methods An electronic search was conducted for published, prospective, cohort studies that reported risk factors for chronic migraine among people with episodic migraine. Risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale. Quality of evidence was determined according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines. Effect estimates were retrieved and summarized using risk ratios. Results Of 5695 identified publications, 11 were eligible for inclusion. The pooled analysis (GRADE system) found “high” evidence for monthly headache day frequency ≥ 10 (risk ratio = 5.95), “moderate” evidence for depression (risk ratio = 1.58), monthly headache day frequency ≥ 5 (risk ratio = 3.18), and annual household income ≥ $50,000 (risk ratio = 0.65) and “very low” evidence for allodynia (risk ratio = 1.40) and medication overuse (risk ratio = 8.82) in predicting progression to chronic migraine. Conclusions High frequency episodic migraine and depression have high quality evidence as predictors of the transformation from episodic migraine to chronic migraine, while annual household income over $50,000 may be protective.

Sign in / Sign up

Export Citation Format

Share Document